In addition, a higher TIDE prediction score in the low F9 expression group was associated not only with poorer immune checkpoint inhibition treatment but also with poorer survival in patients treated with anti-PD1 and anti-CTLA4, implying that F9 may be used as an indicator of immune therapy efficacy for HCC. Here, CTLA4 is linked to hepatocellular carcinoma.